MedIng

History

2024: 1.6-fold increase in cardiac valve prosthesis output

Penza scientific and production enterprise "MedInzh" thanks to the FRP modernized production. Due to this, the production of prostheses of the heart valve with the transcatheter delivery system "MedLab-CT" was increased 1.6 times, and mechanical full-flow prostheses of the heart valve "MedInzh-ST" - 1.2 times. The FRP was informed about this by Zdrav.Expert on September 17, 2024.

source = FRP

Investments in the modernization of production exceeded 300 million rubles, of which 240 million rubles in the form of a preferential loan were provided by the Federal Industrial Development Fund (FRP).

The enterprise with the involvement of a loan from the FRP acquired 41 units of high-tech equipment. Due to this, the production volume of MedLab-KT increased to 260 units per year, and MedInzh-ST to 850 units per year.

source = FRP

In addition, the modernization allowed to increase the level of localization of final products from 60% to 80%, refusing to buy critical materials and components from the USA, Germany and Ireland. By the end of 2024, the company plans to bring this figure to 100%.

Our company produces innovative medical devices comparable to foreign ones. With the similarity of the manufacturing technology of most of the plant's products with foreign ones, Penza introduced the technology of producing pyrolytic carbon for mechanical valves and the technology of processing biomaterial for biological heart valves, "said Alexander Evdokimov, General Director of MedInzh CJSC.

According to the company's estimates, from 30% to 80% of the Russian market for prosthetic heart valve, depending on the segment, is occupied by foreign products, mainly from the USA and Germany. After reaching the design capacity, the market share of the Penza enterprise will grow in the segment of heart valve prostheses with a transcatheter delivery system by 2.5 times - up to 50%, biological prostheses by 4 times - up to 60%, mechanical - from 70% to 80%.

source = FRP

The company produces mechanical and biological prostheses of the heart valve, including with a transcatheter delivery system. They are needed to replace natural heart valves whose function is irreversibly impaired. Valve prostheses are the Penza company's own development, the products are registered in Roszdravnadzor and have passed clinical trials. During testing, the valves demonstrated durability exceeding 100 years.

The key customers of the products are state medical institutions.

2023: Medinj bought 20% of Aniko

In early December 2023, it became known that the Penza company Medinzh, a Russian manufacturer of implantable medical devices for cardiovascular surgery, neurosurgery, traumatology, orthopedics and other areas, became a co-owner of the Aniko startup. This firm develops specialized equipment for cardiac surgery. Read more here.

2021: Investment of 303 million rubles in the production of cardiovascular implants

The MedInzh research and production enterprise invests almost 303 million rubles in the production of cardiovascular implants. This became known at the end of November 2021.

To implement the project, the Industrial Development Fund (FRP) presented a loan of 240 million rubles to the Penza company. The money will go to modernize the production line and purchase new equipment to improve the accuracy of medical device processing. It is assumed that after the update, the company will be able to independently manufacture most of the materials and components imported from abroad, and the level of product localization will approach 100%.

Penza Medical Enterprise attracted 303 million rubles for the production of cardiovascular implants

In addition, MedIng expects to increase labor productivity in the production of cardiovascular implants by 56%. The company estimates the annual potential of the Russian market for implantable products at 9.3 billion rubles, in the total volume of the market "MedInzh" expects 27%.

The NPP "MedInzh" did not name the source of funds that will be used to implement the project, in addition to the loan of the FRP. The Fund provided money in the form of a concessional loan under the Labor Productivity program after signing documents fixing the obligations of the parties.

NPP "MedInzh" produces heart valves, stents, artificial joints and other biomedical products. The company works in the Rameev technopark in the Penza region.

The enterprise carries out its research and production activities under the conditions of an implemented and functioning quality management system that meets the requirements of MS ISO 13485 "Medical Devices. Quality management systems. System requirements for legislative purposes. "

The products of NPP "MedInzh" are supplied to medical institutions providing high-tech and specialized medical care, as well as to cardiocenters and other medical institutions in Russia and the CIS.^[1]

Notes